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ABSTRACT
Vaccination with autologous dendritic cells (DC) loaded ex vivo with melanoma-associated antigens is
currently being tested as an adjuvant treatment modality for resected locoregional metastatic (stage III)
melanoma. Based on its mechanism of action, DC vaccination might potentiate the clinical efficacy of
concurrent or sequential immune checkpoint inhibition (ICI). The purpose of this study was to determine
the efficacy of ICI administered following recurrent disease during, or after, adjuvant DC vaccination. To
this end, we retrospectively analyzed clinical responses of 51 melanoma patients with either irresectable
stage III or stage IV disease treated with first- or second-line ICI following recurrence on adjuvant DC
vaccination. Patients were analyzed according to the form of ICI administered: PD-1 inhibition mono-
therapy (nivolumab or pembrolizumab), ipilimumab monotherapy or combined treatment with ipilimu-
mab and nivolumab. Treatment with first- or second-line PD-1 inhibition monotherapy after recurrence
on adjuvant DC vaccination resulted in a response rate of 52%. In patients treated with ipilimumab
monotherapy and ipilimumab-nivolumab response rates were 35% and 75%, respectively. In conclusion,
ICI is effective in melanoma patients with recurrent disease on adjuvant DC vaccination.
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Introduction
Melanoma is a highly malignant melanocyte-derived neoplasm.
Surgical resection with curative intent is the primary treatment
modality for local and locoregional disease. However, with
advancing stage, surgical curation becomes increasing unlikely
with 5-y melanoma-specific survival rates ranging from 93%
(stage IIIA) to 32% (stage IIID) although the prognosis of
melanoma patients having locoregional disease has likely
improved since the advent of adjuvant systemic therapy.1 In
distant metastatic disease (stage IV melanoma), surgery has
limited value and therapy mainly consists of systemic treatment
with immune checkpoint inhibition (ICI) and targeted therapy.
ICI consists of monoclonal antibodies intended to enhance
the cancer-eradicating capacity of the immune system by
restraining the immune-inhibiting function of CTLA-4 (ipili-
mumab) and PD-1 (nivolumab and pembrolizumab). Stage IV
melanoma patients can be treated with either antibody as
monotherapy or with the combination of ipilimumab and
nivolumab.2–5 For resected stage III melanoma patients, all
of the previous-mentioned agents are approved as monother-
apy, with PD-1 inhibition outperforming ipilimumab.6–8
Besides ICI, targeted therapy with combined BRAF inhibition
and MEK inhibition (BRAF/MEKi) is approved for both the
treatment of stage IV melanoma and the adjuvant treatment
of stage III melanoma.9–12
Over the past years, we extensively studied dendritic cell
(DC) vaccination in both stage III and stage IV melanoma
patients.13–24 DC vaccination involves the administration of
autologous DC matured and loaded ex vivo with melanoma-
associated antigens. DC vaccination aims to eradicate mela-
noma cells by activating melanoma-specific T-cells in vivo. In
stage III patients, adjuvant DC vaccination protocols induced
functional melanoma-specific T-cell responses in 71% of
patients, compared to 23% in metastatic melanoma
patients.13,14 When retrospectively compared to matched his-
torical controls, adjuvant DC vaccination improved overall
survival (OS).13 Although clinical response following DC vac-
cination has been observed in some stage IV patients, DC
vaccination is considerably less effective in these patients
compared to ICI and BRAF/MEKi.15,25 Therefore, in mela-
noma, we focus on the adjuvant application of DC vaccina-
tion, with a phase III trial currently ongoing (NCT02993315).
The high rate of immune induction following adjuvant DC
vaccination offers unique possibilities for its positioning
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within the systemic treatment landscape of melanoma. Based
on its mechanism of action, DC vaccination might potentiate
the clinical efficacy of concurrent or sequential ICI treatment.
The potential synergy between ICI and DC vaccination can be
explained using the cancer-immunity cycle proposed by Chen
and Mellman.26 This cycle illustrates the steps cytotoxic
T-cells have to complete before cancer cells can successfully
be eradicated. Failure to complete any of these processes
results in the incomplete clearance of malignant cells. DC
vaccination aims to improve the activation of naive T-cells,
whilst ICI is intended to reduce T-cell inhibition. Therefore,
both modalities may be complementary as they act on differ-
ent steps of the cancer-immunity cycle.27
In this study, we explore the clinical outcome of patients
treated with PD-1 inhibition monotherapy or ipilimumab-
nivolumab following recurrence on adjuvant DC vaccina-
tion for completely resected stage III disease. In addition,
we present updated data on ipilimumab monotherapy fol-
lowing recurrence on adjuvant DC vaccination.
Materials and methods
Patients and treatment
We retrospectively analyzed patients treated with ICI (nivo-
lumab, pembrolizumab or ipilimumab monotherapy, or ipili-
mumab-nivolumab) for recurrent disease after receiving DC
vaccination for the adjuvant treatment of resected stage III
cutaneous melanoma. All patients were treated with adjuvant
DC vaccination between August 2004 and August 2018 in
different study protocols (supplementary table 1). Briefly,
vaccines consisted of autologous monocyte-derived or natu-
rally circulating DC loaded with melanoma antigens. Patients
were treated with three biweekly DC vaccinations (one cycle),
with two additional cycles at six-month intervals in the
absence of recurrent disease. Patients were evaluated every
3–6 months by medical history and physical examination.
Imaging was performed at the discretion of the physician,
except in the MIND-DC trial (NCT02993315) in which CT
scanning was performed consistently during the follow-up
visits. All DC vaccination studies were approved by the appro-
priate ethical review boards and written informed consent was
obtained from all patients.
After disease recurrence on adjuvant DC vaccination,
patients who received ICI as first- or second-line treatment
for metastatic disease were evaluated for response, progres-
sion-free survival (PFS) and OS. Patients started ICI between
October 2008 and December 2018. Later patients were
excluded due to short follow-up at the time of analysis
(March 2019). Patients were analyzed according to the type
of ICI administered: PD-1 inhibition monotherapy, ipilimu-
mab monotherapy or ipilimumab-nivolumab. Ipilimumab
monotherapy was administered at a dose of 3 mg/kg for
four cycles to all patients except one. This patient received
ipilimumab monotherapy in a compassionate use program at
a dose of 10 mg/kg for four cycles followed by 10 mg/kg
every 12 weeks as maintenance therapy. Patients treated with
PD-1 inhibition monotherapy received pembrolizumab
2 mg/kg every 3 weeks, nivolumab 3 mg/kg every 2 weeks
or nivolumab 480 mg fixed dose every 4 weeks. All patients
treated with ipilimumab-nivolumab received nivolumab at
a dose of 1 mg/kg plus ipilimumab at a dose of 3 mg/kg
every 3 weeks for four doses, followed by nivolumab at
a dose of 3 mg/kg every 2 weeks. Patients were treated
until scheduled therapy end, progressive disease (PD), unac-
ceptable toxicity or a treatment pause in the setting of dis-
ease response.
Immunological monitoring
In the DC vaccination trials, the immunological response
was monitored after each DC vaccination cycle except in
the MIND-DC trial in which immunological response was
determined only following the first cycle. Immunological
response was tested using delayed-type hypersensitivity
(DTH) skin tests as described previously.14 Briefly, patients
received intradermal injections of DC loaded with melanoma
antigens. After 48 h, 6 mm punch biopsies were taken from
the injected skin. In these biopsies, skin-test infiltrating
lymphocytes (SKIL) were analyzed for antigen-specific
T-cells using multimeric-MHC complexes containing the
relevant antigen epitopes. Furthermore, the presence of
functional T-cells in the SKIL was assessed by measuring
the interferon (IFN)-γ production upon stimulation with
melanoma-associated antigen (supplementary figure 1).
Patients with functional T-cells producing IFN-γ and/or
having antigen-specific T-cells in at least one of the DTH
skin tests were considered to have a melanoma-specific
immunological response.
Response evaluation
Patients underwent radiological evaluations during ICI using
CT which were planned every 3 months with the possibility of
extended intervals when patients experienced durable stable
disease, partial (PR) or complete response (CR). Responses
were assessed using Response Evaluation Criteria in Solid
Tumors (RECIST) version 1.1.28 Most patients (86%) were
evaluated for the presence of cerebral metastases using MRI or
CT prior to ICI start. The response rate is calculated as the
portion of patients experiencing a PR or CR. The disease
control rate is defined as the portion of patients experiencing
stable disease, PR or CR.
Statistical analysis
Survival data were calculated using the Kaplan–Meier
method. OS is defined as the time from the initiation of ICI
until death from any cause. PFS is the time from the first
administration of ICI until PD. Median follow-up time was
calculated with the Kaplan–Meier method, using the date of
ICI start to the date of last follow-up and censoring for
death.29 Correlation between immunological outcome during
DC vaccination and survival parameters on subsequent ICI
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treatment was determined using a log-rank test. Correlation
between immunological outcome during DC vaccination and
clinical response was assessed using a Fisher’s Exact test. SPSS
software version 25 (SPSS Inc., Chicago, IL) and GraphPad
version 5.03 (GraphPad Software Inc., San Diego, CA) were
used for statistical analysis.
Results
Patient and treatment characteristics
A total of 51 patients received ICI as first- and/or second-line
treatment for unresectable stage III or stage IV melanoma
after recurrence on adjuvant DC vaccination. Median recur-
rence-free survival on adjuvant DC vaccination was
7.9 months. All patients received at least one DC vaccine
with 47 patients completing at least one cycle of three DC
vaccines. As introduced before, patients were analyzed in
three separate treatment groups (PD-1 inhibition monother-
apy, ipilimumab monotherapy and ipilimumab-nivolumab)
(Figure 1). Baseline characteristics of the patients in each
treatment group are shown in Table 1.
Clinical efficacy of ICI following recurrence on adjuvant
DC vaccination
Median follow-up time, from the first administration of ICI,
was 10 months for patients treated with PD-1 inhibition
monotherapy, 66 months for patients treated with ipilimumab
monotherapy and 13 months for patients to whom ipilimu-
mab-nivolumab was given.
Response rates following ICI are shown in Table 2. The
response rate in patients treated with first- or second-line PD-
1 inhibition monotherapy was 52%. In the ipilimumab-
nivolumab group, the highest response rate (75%) was
observed following first- or second-line treatment. In patients
treated with first- or second-line ipilimumab monotherapy,
the lowest response rate was seen, 35%.
Kaplan–Meier curves depicting PFS and OS of patients
receiving first- or second-line ICI in different treatment groups
are shown in Figure 2. There were no significant differences
found in PFS and OS between first- and second-line PD-1
inhibition monotherapy or first- and second-line ipilimumab
monotherapy (data not shown). First- and second-line ipilimu-
mab-nivolumab were not analyzed separately as only two
patients received second-line ipilimumab-nivolumab.
PFS rates after 1 and 2 y were 53% and 34% for patients
treated with PD-1 inhibition monotherapy, respectively. After
1 y, 37% of the patients treated with ipilimumab monotherapy
were free of progression. The 2- and 5-y PFS rates following
ipilimumab monotherapy were 37% and 31%, respectively.
Following PD-1 inhibition monotherapy, 93% of patients
were alive after 1 y, after 2 y this was 66%. One, 2- and 5-y OS
rates for ipilimumab monotherapy were 73%, 50% and 39%,
respectively. For patients treated with ipilimumab-nivolumab,
1-y PFS and OS rates were 50% and 66%, respectively, but
follow-up in this treatment group is limited.
Immunological response on DC vaccination and the
subsequent clinical efficacy of ICI
No correlation between the presence of a melanoma-specific
immunological response after DC vaccination and PFS or OS
after ICI treatment was found in any of the treatment groups
(data not shown). Neither was a melanoma-specific immuno-
logical response during DC vaccination more prevalent in
ICI-responding patients compared to patients not responding
to ICI (supplementary figures 1 and 2).
Discussion
ICI following recurrence on adjuvant DC vaccination led to
clinical benefit in a considerable portion of metastatic mela-
noma patients. Clinical response was observed in 52% of the
patients treated with first- or second-line PD-1 inhibition
monotherapy. In the ipilimumab monotherapy and the ipili-
mumab-nivolumab groups, 35% and 75% of patients
responded to treatment, respectively.
Of the patients treated with PD-1 inhibition monotherapy,
the majority had no cerebral metastases and a normal lactate
dehydrogenase (LDH), both positive predictors for response
and survival.30,31 This patient selection resulted from
Figure 1. First- and second-line treatment in metastatic melanoma patients
following recurrent disease on adjuvant dendritic cell vaccination. First-
and second-line treatment is shown for the patients in the three different
treatment groups. Three patients received first-line PD-1 inhibition monotherapy
followed by second-line ipilimumab monotherapy, another three patients were
treated with first-line ipilimumab monotherapy after which they
received second-line PD-1 inhibition monotherapy. These six patients were
analyzed in both the PD-1 inhibition monotherapy group (red) and the ipilimu-
mab monotherapy group (blue). Therefore, the three treatment groups com-
bined consisted of 57 analyzed patients.
Abbreviations: ICI, immune checkpoint inhibition; ipi, ipilimumab; ipi-nivo, com-
bined treatment with ipilimumab and nivolumab; mono, monotherapy.
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treatment guidelines in the institutions were patients received
ICI. According to these guidelines, patients lacking an ele-
vated LDH, cerebral metastases, high tumor load and rapid
disease progression should preferably be treated with PD-1
inhibition monotherapy instead of ipilimumab-nivolumab.
When taking the favorable characteristics in account, the
response rate of 52% of the PD-1 inhibition monotherapy
cohort is similar to the 51% response rate reported in com-
parable patients (i.e. patients with a normal LDH and no
active cerebral metastases) following nivolumab
monotherapy.31
The observed response rate of 35% in patients treated with
ipilimumab monotherapy is higher than the response rates of
11–19% reported of ipilimumab monotherapy in melanoma
patients without prior DC vaccination.32–34 However, the
comparison between our cohort and the published data is
complicated by differences in patient characteristics. In the
published trials, the presence of active cerebral metastases was
an exclusion criterion (with 5–11% of patients having treated
cerebral metastases). In our cohort, 20% of patients had cere-
bral metastases of which 75% were treated. The portion of
patients having an elevated LDH was slightly lower in our
cohort (20%), compared to 33–39% in published trials. Lastly,
in our cohort, a portion of patients received prior PD-1
inhibition monotherapy (15%) or BRAF inhibition (20%). In
the landmark studies, a minority (0–20%) of patients received
prior targeted therapy with no patients receiving PD-1 inhibi-
tion monotherapy before ipilimumab monotherapy. As
responses to ipilimumab monotherapy after progressive dis-
ease on PD-1 inhibition monotherapy are reported to be
similar to first-line ipilimumab monotherapy, we regard the
influence of prior PD-1 inhibition monotherapy on response
rates to be limited.35
All patients in our ipilimumab-nivolumab cohort had an
elevated LDH, cerebral metastases and/or rapid disease pro-
gression before the start of ICI. Despite these unfavorable
characteristics, our ipilimumab-nivolumab cohort showed
a response rate of 75% which is higher than the 58%
response rate described in literature.34 However, our results
may be biased as our small cohort is prone to sampling
errors, complicating extrapolation to larger numbers of
patients.
Table 1. Patient baseline characteristics at the start of immune checkpoint inhibition.
PD-1 inhibition monotherapy after DC
vaccination (n = 29)
Ipilimumab monotherapy after DC
vaccination (n = 20)
Ipilimumab-nivolumab after DC
vaccination (n = 8)
Age
Mean (range) 55 (37–74) 53 (24–69) 60 (43–78)
Sex
Male 17 (59%) 17 (85%) 8 (100%)
Female 12 (41%) 3 (15%) 0
Number of completed cycles of
DC vaccination
0 (1 or 2 vaccines) 2 (7%) 0 2 (25%)
1 14 (48%) 3 (15%) 4 (50%)
2 6 (21%) 6 (30%) 1 (13%)
3 7 (24%) 11 (55%) 1 (13%)
Stage (AJCC 7th ed.) at start of ICI
Unresectable stage III 5 (17%) 0 0
M1a 5 (17%) 3 (15%) 1 (13%)
M1b 8 (28%) 5 (25%) 0
M1c 11 (38%) 12 (60%) 7 (88%)
BRAF mutation
V600 mutation 16 (55%) 10 (50%) 6 (75%)
No V600 mutation 13 (45%) 5 (25%) 2 (25%)
Unknown 0 5 (25%) 0
Lactate dehydrogenase
≤ULN 26 (90%) 16 (80%) 3 (38%)
>ULN 3 (10%) 4 (20%) 5 (63%)
Cerebral metastases
Yes 0 4 (20%) 2 (25%)
No 24 (83%) 14 (70%) 6 (75%)
Unknown 5 (17%) 2 (10%) 0
Local treatment for cerebral
metastasesa
No treatment N/A 0 1 (50%)
Surgery N/A 1 (25%) 0
Radiotherapy N/A 3 (75%) 1 (50%)
Line of treatment
First 24 (83%) 10 (50%) 6 (75%)
Second 5 (17%) 10 (50%) 2 (25%)
Prior systemic treatment
None 24 (83%) 10 (50%) 6 (75%)
Dacarbazine 0 3 (15%) 0
PD-1 inhibition monotherapy N/A 3 (15%) 0
BRAF/MEKi 2 (7%) 0 2 (25%)
BRAFi monotherapy 0 4 (20%) 0
Ipilimumab monotherapy 3 (10%) N/A 0
apercentage of patients having cerebral metastases.
Abbreviations: AJCC, American Joint Committee on Cancer; BRAF/MEKi, BRAF/MEK inhibition; BRAFi, BRAF inhibition; DC, dendritic cell; ICI, immune checkpoint
inhibition; N/A, not applicable; ULN, upper limit of normal.
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The present study has some limitations. First, data
obtained from literature may represent a slightly different
patient population with regard to prognosis, impeding
a fair comparison with our cohort. Second, OS in this
study may have been confounded as a portion of patients
received other treatment lines besides first- or second-line
ICI. However, response rates are influenced little by prior
treatment lines and not at all by subsequent treatment
lines.
No correlation between the presence of a melanoma-
specific immunological response after DC vaccination and
clinical response or survival on subsequent ICI treatment
was found. This is unsupportive of the concept that DC
vaccination activates the immune system resulting in
improved clinical outcome on subsequent ICI. The
absence of such a correlation may have several reasons.
First, all patients analyzed in this study were refractory to
DC vaccination. Therefore, although melanoma-specific
T cells could be detected after DC vaccination, the
T cells might not have been susceptible for stimulation
with ICI. Second, the response to the chosen target (mel-
anoma-associated antigens) might be too weak to translate
into clinical effect (possibly in contrast to neo-antigens).
Third, it may be that our method of immunological mon-
itoring does not capture the complete spectrum of
immune induction following DC vaccination. Finally, our
immunomonitoring method only conveys a snapshot of
the T-cell status at the moment of testing, and may there-
fore not be representative of the T-cell status at the time
of ICI.
Still, sequential DC vaccination potentially has synergy
with ICI. Recent work by Linette et al. strengthens this idea
as it implicates immunological ignorance of clonal neoanti-
gens as the basis for ineffective T-cell immunity and
suggested to employ DC vaccination as an adjunct to
ICI.36 Our group has previously demonstrated that treat-
ment with ipilimumab following recurrence on DC vacci-
nation might result in improved clinical efficacy of
ipilimumab.37 Furthermore, concurrent administration of
DC vaccination and ipilimumab has been tested in two
clinical studies, showing the suggestion of synergy with
little added toxicity.38,39 Studies investigating whether DC
vaccination potentiates PD-1 inhibition in the treatment of
metastatic melanoma are currently ongoing.
This study shows that sequential ICI treatment follow-
ing recurrence on adjuvant DC vaccination remains at
least as effective as ICI treatment without prior adjuvant
DC vaccination. This is important as it is currently
unclear how to treat patients when recurrence occurs
during, or shortly after, adjuvant treatment with either
BRAF/MEKi or ICI. Unless a long treatment-free interval
is present, re-introducing the same drug to treat recurrent
disease arising during adjuvant therapy will most likely
not be beneficial. Although vaccination is currently not
an approved agent for the adjuvant treatment of stage III
melanoma, it may prove to be effective in the currently
ongoing phase III trial (NCT02993315). This possibly cre-
ates the opportunity to treat patients with DC vaccination
in the adjuvant setting and leave ICI as a treatment option
in case of recurrence.
In conclusion, ICI remains a viable treatment option for
melanoma patients in case of recurrence on adjuvant DC
vaccination. This adds to the notion that DC vaccination as
an adjunct to ICI (either sequentially or concurrently) may
have a role within the future treatment landscape of mela-
noma. Evidently, the therapeutic efficacy of adjuvant DC
vaccination has to be proven, a phase III trial to that end is
currently ongoing.
Table 2. Clinical efficacy of immune checkpoint inhibition following dendritic cell vaccination.
PD-1 inhibition
monotherapy after
DC vaccination (n = 29)
Ipilimumab monotherapy
after DC vaccination
(n = 20)
Ipilimumab- nivolumab after
DC vaccination
(n = 8)
Response rate 15 (52%) 7 (35%) 6 (75%)
Disease control rate 21 (72%) 10 (50%) 6 (75%)
Best response on ICI
Complete response 7 (24%) 4 (20%) 2 (25%)
Partial response 8 (28%) 3 (15%) 4 (50%)
Stable disease 6 (21%) 3 (15%) 0
Progressive disease 8 (28%) 10 (50%) 2 (25%)
Median progression-free survival (months) 13.1 3.9 5.6
Median overall survival (months) 32.5 30.0 NR
Systemic treatment after progressive disease on ICIa
No treatment for progressive disease 7 (41%) 4 (29%) 2 (50%)
Dacarbazine 0 1 (7%) 0
BRAF/MEKi 5 (29%) 1 (7%) 2 (50%)
BRAFi monotherapy 0 3 (21%) 0
(Re-introduction) Ipilimumab monotherapy 4 (24%) 0 0
(Re-introduction) PD-1 inhibition monotherapy 2 (12%) 7 (50%) 0
Ipilimumab-nivolumab 1 (6%) 1 (7%) 0
Treatment in a clinical trial 0 3 (21%) 0
apercentage of the number of patients with progressive disease, patients may have been treated with multiple agents after progressive disease on immune
checkpoint inhibition.
Abbreviations: BRAF/MEKi, BRAF/MEK inhibition; BRAFi, BRAF inhibitor; DC, dendritic cell; ICI, immune checkpoint inhibition; NR, not reached.
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